Cyclerion Therapeutics, Inc. - Special Call Transcript
Ladies and gentlemen, thank you for standing by and welcome to the Cyclerion Therapeutics Webcast and Conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I'd now like to hand the conference over to Jessi Rennekamp. Please go ahead.
Good morning. Thank you for joining this morning's call on our praliciguat Phase II results. I'm Jessi Rennekamp in Cyclerion Investor Relations. I'm joined by Peter Hecht, Chief Executive Officer; Chris Wright, Chief Medical Officer; Andy Busch, Chief Innovation Officer; Bill Huyett, Chief Financial Officer; and other members of the management team who are here to answer questions.
Today's discussion contains forward-looking statements. Such statements are based on current expectations and assumptions that are subject to risks and uncertainties and involve a number of risk factors that could cause actual results to differ materially from those we expect. For a discussion of material
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |